Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia

Simple item page
dc.contributor.authorOkusanya, BO
dc.contributor.authorOladapo, OT
dc.contributor.authorLong, Q
dc.contributor.authorLumbuganon, P
dc.contributor.authorCarroli, G
dc.contributor.authorQureshi, Z
dc.contributor.authorDuley, L
dc.contributor.authorSouza, JP
dc.contributor.authorGulmezoglu, AM
dc.date.accessioned2022-01-20T09:05:55Z
dc.date.available2022-01-20T09:05:55Z
dc.date.issued2016
dc.descriptionScholarly articleen_US
dc.description.abstractBackground: The pharmacokinetic basis of magnesium sulphate MgSO4) dosing regimens for eclampsia prophylaxis and treatment is not clearly established. Objectives: To review available data on clinical pharmacokinetic properties of MgSO4 when used for women with pre-eclampsia and/or eclampsia. Search strategy: MEDLINE, EMBASE, CINAHL, POPLINE, Global Health Library and reference lists of eligible studies. Selection criteria: All study types investigating pharmacokinetic properties of MgSO4 in women with pre-eclampsia and/or eclampsia. Data collection and analysis: Two authors extracted data on basic pharmacokinetic parameters reflecting the different aspects of absorption, bioavailability, distribution and excretion of MgSO4 according to identified dosing regimens. Main results: Twenty-eight studies investigating pharmacokinetic properties of 17 MgSO4 regimens met our inclusion criteria. Most women (91.5%) in the studies had pre-eclampsia. Baseline serum magnesium concentrations were consistently <1 mmol/l across studies. Intravenous loading dose between 4 and 6 g was associated with a doubling of this baseline concentration half an hour after injection. Maintenance infusion of 1 g/hour consistently produced concentrations well below 2 mmol/l, whereas maintenance infusion at 2 g/hour and the Pritchard intramuscular regimen had higher but inconsistent probability of producing concentrations between 2 and 3 mmol/l. Volume of distribution of magnesium varied (13.65–49.00 l) but the plasma clearance was fairly similar (4.28–5.00 l/hour) across populations. Conclusion: The profiles of Zuspan and Pritchard regimens indicate that the minimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted level. Exposure–response studies to identify effective alternative dosing regimens should target concentrations achievable by these standard regimens.en_US
dc.identifier.citationOkusanya BO, Oladapo OT, Long Q, Lumbiganon P, Carroli G, Qureshi Z, Duley L, Souza JP, Gulmezoglu AM. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG 2016; 123(3):356-66.en_US
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/10619
dc.language.isoenen_US
dc.subjectEclampsiaen_US
dc.subjectMagnesium sulphateen_US
dc.subjectPharmacokineticsen_US
dc.subjectSerum magnesiumen_US
dc.subjectResearch Subject Categories::MEDICINE::Surgery::Obstetrics and women's diseases::Obstetrics and gynaecologyen_US
dc.titleClinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsiaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Clinical pharmacokinetic properties of magnesium sulphate in women with preeclapsia and eclampsia.pdf
Size:
234.39 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Obstetrics and Gynaecology- Scholarly Publications